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Introduction
The hepatocerebral forms of mtDNA depletion
syndromes typically manifest soon after birth
and cause premature death in childhood [1].
Presentation is usually with early liver failure,
followed by development delay and muscle
weakness during the first year of life, as well as
lactic acidosis and hypoglycemia [2]. These
conditions are associated with mutations in at
least six genes [3] though further heterogeneity
is expected. An ample array of MPV17
mutations (Figure 1) has been described in
about 30 patients from different ethnicities.
Figure 1 - Described mutations in the MPV17 gene. ○
Missense mutation; ● Nonsense mutation; ∆ Small deletion;
▲ Gross deletion; ◊ Small insertion; □ Splicing mutation; ■
c.186+2T>C.
Patients
We describe a Brazilian infant, the second child
of apparently unrelated healthy parents, who
presented neonatal hypoglycemia, digestive
bleeding and sepsis in the first week of life.
Laboratory tests also showed elevated levels of
total and free serum bilirubin and
transaminases. Amino acids were normal
whereas organic acids revealed the presence
of lactic acid (3X normal values) and Krebs
cycle intermediates at age 2 months. Shortly
after the patient manifested failure to thrive,
severe hypotonia, nystagmus, poor
echoarchitecture at liver ultrasound, and
cirrhotic ascites. He died at 5-months-old with
hepatic insufficiency associated with bleeding
and multiple organ failure.
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Results
The patient presented severe mtDNA depletion
(residual mtDNA levels were 2% in liver and
23% in muscle) and molecular studies detected
a homozygous mutation c.186+2T>C in
MPV17, a variant already reported in a
heterozygous state with poor prognosis in a
singleton [4]. This mutation is located at the
invariant splice donor site and is predicted to
abolish the splicing donor site of exon 3
(http://www.cbs.dtu.dk/services/NetGene2 and
http://www.fruitfly.org). The c.186+2T>C was
also detected in the proband’s elder sister who
had presented at birth with neonatal
hypoglycemia, failure to thrive and hepatic
insufficiency, later developed seizures and
hypotonia, and died at 10 months. The
mutation was heterozygous in the parents who
were from nearby villages in south Brazil.
Discussion/Conclusion
To date a total of 32 patients have been
reported with MPV17 mutations. Our study
expands the ethnic background of MPV17-
mutated patients and will be important for an
accurate genetic counseling and a prenatal
diagnosis to the affected family. MtDNA
depletion should be looked for in neonates with
progressive cholestasis and neurological
deterioration.
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